Recent

% | $
Quotes you view appear here for quick access.

Microsoft Corporation Message Board

  • biotechboygenius biotechboygenius Jul 2, 2006 7:17 PM Flag

    GTCB looks really cheap..

    Take a look, you'll be impressed at the potential. Check out Investors Hub - Biotech values for more details.

    gtcb from rodman

    ATRYN RECEIVES POSITIVE CHMP OPINION GTC Biotherapeutics announced
    > today that the Committee for Medicinal Products for Human Use (CHMP)
    > of the European Medicines Agency (EMEA) has adopted a positive opinion
    > on the market authorization application (MAA) for ATryn for the
    > prophylaxis of venous thromboembolism surgery of patients with
    > congenital antithrombin deficiency. ATryn may be given in combination
    > with heparin or low molecular weight heparin, which are used during
    > these surgeries. EMEA routinely accepts recommendation of CHMP.
    > Therefore, we expect final market authorization by the E.U. in about
    > three months. ATryn, once approved, will be the first antithrombin
    > product approved for use in all 25 countries of the E.U.
    > ATRYN - FIRST EVER TRANSGENIC PROTEIN LIKELY TO BE APPROVED - A
    > SIGNIFICANT MILESTONE FOR THE INDUSTRY The positive CHMP opinion is an
    > unusual reversal following a review of GTC's petition of
    > re-examination of a prior negative opinion. While congenital
    > antithrombin deficiency is a very small indication from which GTCB
    > will not derive significant commercial value, ATyn approval is in fact
    > a milestone achievement for GTCB. This is the first time ever that a
    > transgenic goat product is approved for any indication, which serves
    > to validate GTCB's proprietary technology platform. LEO Pharma, GTCB's
    > European partner, will be responsible for the commercialization of
    > ATryn in the E.U. for the approved indication and has selected
    > disseminated intravascular coagulation (DIC) as an acquired
    > antithrombin deficiency indication to develop a large market
    > opportunity for ATryn in the E.U. Leo is expected to start a Phase II
    > trial by YE06. Future success of ATryn in an acquired indication will
    > be critical to the long-term prospects of GTCB.
    > Raising GTCB to Market outPerform We are greatly encouraged by the
    > reversal of CHMP's opinion regarding the approvability of ATryn. It
    > not only validates the technology platform but also greatly increases
    > our confidence in the company management's ability to execute with
    > regard to regulatory maters. We are strong believers in GTCB's
    > technology platform and expect more companies to adopt it as a way to
    > produce complicated protein therapeutics. We believe the decision by
    > Leo Pharm to move forward with ATryn in DIC, a large acquired
    > antithrombin deficiency indication, is definitely a positive
    > development for GTCB. Using the sales multiple of 6X our 2013 ATryn
    > revenue estimate of approximately $226 MM and a 30% annual discount
    > rate that we believe adequately compensates investors for the risks
    > associated with GTCB, we derive a 12-month price target of $4.
    > KEY RISK US ATryn trial setback
    >
    >
    > <<GTCB 06-02-06 Upgrade Final.pdf>>
    >
    > Navdeep S. Jaikaria, Ph.D.
    > Managing Director
    > Senior Biotechnology Analyst
    > H<http://www.rodmanandrenshaw.com/>H
    > Tel:: 212 356 0538
    > Fax:: 212 356 0546

 
MSFT
41.62-0.54(-1.29%)Apr 17 4:00 PMEDT